Clinical trial NCT02789917: APixaban vs. PhenpRocoumon in Patients With ACS and AF: APPROACH-ACS-AF
Official title: APixaban Versus PhenpRocoumon: Oral AntiCoagulation Plus Antiplatelet tHerapy in Patients With Acute Coronary Syndrome and Atrial Fibrillation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Acute Coronary Syndrome
Atrial Fibrillation
Coronary Artery Disease
Keywords: ACS
Triple-Therapy
AF
oral anticoagulation (OAC)
non-vitamin-K oral anticoagulant (NOAC)
Lead sponsor: LMU Klinikum
Sponsor class: OTHER
Collaborators: name: Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
name: Technical University of Munich
name: Helmholtz Zentrum München
name: University of Göttingen
name: University of München
name: University Medicine Greifswald
First posted: 2016-06-03
Enrollment: 403
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: It is hypothesised that a dual therapy strategy by oral anticoagulation with the new Factor-Xa-inhibitor apixaban plus clopidogrel is superior to a triple therapy regimen with phenprocoumon plus acetylsalicylic acid (ASA) and clopidogrel with respect to avoiding bleeding events in patients with atrial fibrillation undergoing percutaneous coronary intervention in the setting of an acute coronary syndrome.

Detailed description: Patients with atrial fibrillation (AF) presenting an acute coronary syndrome (ACS) and undergoing PCI require a triple therapy with a combination of oral anticoagulation (OAC) and dual anti-platelet therapy. Current guidelines recommend a regimen consisting of aspirin, clopidogrel and an oral anticoagulant. Although effective in preventing recurrent ischemia, triple therapy confers an elevated bleeding risk, which also has a major impact on the patients' prognosis and survival. Data from one randomized trial suggest that omitting aspirin in patients with indication for triple therapy may reduce the risk of bleeding without an increase of the rate of ischemic events. In addition, the recently introduced non-vitamin-K oral anticoagulants (NOACs) show less bleeding events as compared to vitamin-K antagonist in AF patients. In this trial it is postulated that a dual therapy consisting of the factor-Xa inhibitor apixaban and clopidogrel is associated with significant lower bleeding rates as compared to traditional triple therapy with aspirin, clopidogrel and a vitamin K antagonist (VKA). To test this hypothesis, patients with atrial fibrillation, who underwent PCI in the setting of an ACS will be randomized to either a dual therapy (apixaban+clopidogrel) or a triple therapy (aspirin+clopiodgrel+VKA). The patients will be followed-up for 6 months after randomization.

Eligibility criteria: Inclusion Criteria:

* Signed written informed consent
* Patients with an ACS after successful percutaneous coronary intervention
* Indication for oral anticoagulation due to non-valvular atrial fibrillation or atrial flutter (CHA2DS2VASc score ≥ 2)
* Males and Females, ages ≥ 18
* Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug.
* Women must not be breastfeeding
* WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drugs plus 30 days (duration of ovulatory cycle) post-treatment completion. However they must still undergo pregnancy testing.

Exclusion Criteria:

* Age \< 18 years
* History of intracranial bleeding
* Active bleeding
* History of TIMI major bleeding according to TIMI and/or type ≥3b BARC criteria in the last 6 months
* History of peptic ulcer in the last 6 months
* Subjects with a history of a complicated or prolonged cardiogenic shock in the last two weeks prior to randomization. A complicated or prolonged cardiogenic shock is defined by a cardiogenic shock that required mechanical ventilation or the cardiovascular support with positive inotropic drugs (i.v. catecholamine) for ≥7 days
* Planned major surgery during the study course with planned discontinuation of antithrombotic therapy
* Expected life expectancy of less than a year and/or severe illness (e.g. malignancy)
* Mechanical valve replacement
* Valvular atrial fibrillation
* Severe renal insufficiency (creatinine clearance \< 30ml/min)
* Severe liver insufficiency (Child-Pugh-class C) or elevated hepatic transaminases \>2 times the upper limit of normal
* Patient's inability to fully comply with the study protocol
* Known or persistent abuse of medication, drugs or alcohol reliable by the investigator in individual cases
* Subjects with known contraindications to apixaban, phenprocoumon, clopidogrel or ASA treatment, which are hypersensitive to the drug substance or any component of the product
* Relevant hematologic deviations: platelet count \< 50 G/L or platelet count \> 600 G/L
* Current or planned pregnancy or nursing women, women 90 days after childbirth. Females of childbearing potential, who do not use and are not willing to use medically reliable methods of contraception for the entire study duration (such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices) unless they are surgically sterilized / hysterectomized or there are any other criteria considered sufficiently

Primary outcomes:
measure: The combined endpoint of moderate or major bleeding complications during the initial hospitalization and follow up (Bleeding Academic Research Consortium (BARC) type ≥ 2 bleeding)
timeFrame: up to 6 months after randomization
Secondary outcomes:
measure: Combined event of death, myocardial infarction, definite stent thrombosis, stroke/other systemic thromboembolism and all the individual components of the composite secondary endpoint
timeFrame: up to 6 months after randomization
measure: Bleeding complications (Major bleeding: BARC > 3b bleeding)
timeFrame: up to 6 months after randomization
Other outcomes:
Locations:
city: Munich
country: Germany
facility: Munich University Hospital
state: Bavaria
city: Aachen
country: Germany
facility: Universitätsklinikum der RWTH Aachen
city: Berlin
country: Germany
facility: Charité, Campus Benjamin Franklin
city: Berlin
country: Germany
facility: Charité, Campus Virchow-Klinikum
city: Coburg
country: Germany
facility: Klinikum Coburg
city: Essen
country: Germany
facility: Westdeutsches Herzzentrum am Universitätsklinikum
city: Greifswald
country: Germany
facility: Universitätsmedizin Greifswald
city: Göttingen
country: Germany
facility: Universitätsmedizin Göttingen
city: Heidelberg
country: Germany
facility: Universitätsklinikum Heidelberg
city: Kiel
country: Germany
facility: UKHS Campus Kiel
city: Lüdenscheid
country: Germany
facility: Klinikum Lüdenscheid
city: Mainz
country: Germany
facility: Universitätsmedizin Mainz
city: Mannheim
country: Germany
facility: Universitätsklinikum Mannheim
city: München
country: Germany
facility: Klinikum Augustinum
city: München
country: Germany
facility: Städtisches Klinikum München-Neuperlach
city: Rostock
country: Germany
facility: Universitätsmedizin Rostock
Study officials:
affiliation: Klinikum der Universität München (LMU)
name: Reza Wakili, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Klinikum der Universität München (LMU)
name: Steffen Massberg, Prof.
role: STUDY_CHAIR
References: